SEARCH

SEARCH BY CITATION

References

  • Adachi Y, Shibai Y, Mitsushita J, Shang WH, Hirose K, Kamata T (2008). Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. Oncogene 27: 49214932.
  • Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd ed. Br J Pharmacol 153 (Suppl 2): S1209.
  • Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F et al. (2006). Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 98: 236244.
  • Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I et al. (2006). In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57: 709718.
  • Banfi B, Schrenzel J, Nusse O, Lew DP, Ligeti E, Krause KH et al. (1999). A novel H(+) conductance in eosinophils: unique characteristics and absence in chronic granulomatous disease. J Exp Med 190: 183194.
  • Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF et al. (1998). Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16: 27392744.
  • Bedard K, Krause KH (2007). The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245313.
  • Benhar M, Dalyot I, Engelberg D, Levitzki A (2001). Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21: 69136926.
  • Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F et al. (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663671.
  • Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V et al. (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol 19: 12881292.
  • de Carvalho DD, Sadok A, Bourgarel-Rey V, Gattacceca F, Penel C, Lehmann M et al. (2008). Nox1 downstream of 12-lipoxygenase controls cell proliferation but not cell spreading of colon cancer cells. Int J Cancer 122: 17571764.
  • Chou TC, Talalay P (1981). Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207216.
  • Chou TC, Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 2755.
  • Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S et al. (2000). Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 20532063.
  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337345.
  • D'Autreaux B, Toledano MB (2007). ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813824.
  • Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP et al. (2007). Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96: 11661169.
  • Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 57055712.
  • Doroshow JH (2006). Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity. J Natl Cancer Inst 98: 223225.
  • El-Akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ et al. (1996). Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105: 514.
  • Fantini J, Abadie B, Tirard A, Remy L, Ripert JP, el Battari A et al. (1986). Spontaneous and induced dome formation by two clonal cell populations derived from a human adenocarcinoma cell line, HT29. J Cell Sci 83: 235249.
  • Gianni D, Bohl B, Courtneidge SA, Bokoch GM (2008). The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1. Mol Biol Cell 19: 29842994.
  • Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 30703074.
  • Hwang IT, Chung YM, Kim JJ, Chung JS, Kim BS, Kim HJ et al. (2007). Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem Biophys Res Commun 359: 304310.
  • Iannello A, Ahmad A (2005). Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24: 487499.
  • Jackson AL, Loeb LA (2001). The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477: 721.
  • Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE et al. (2008). Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 105: 71477152.
  • Lau AT, Wang Y, Chiu JF (2008). Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 104: 657667.
  • Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A et al. (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65: 948956.
  • Laurent E, McCoy JW 3rd, Macina RA, Liu W, Cheng G, Robine S et al. (2008). Nox1 is over-expressed in human colon cancers and correlates with activating mutations in K-Ras. Int J Cancer 123: 100107.
  • Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY et al. (2005). Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer 113: 510511.
  • Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 39923995.
  • Mitsushita J, Lambeth JD, Kamata T (2004). The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64: 35803585.
  • Morazzani M, de Carvalho DD, Kovacic H, Smida-Rezgui S, Briand C, Penel C (2004). Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: implication of ROS-P38 MAPK-integrin alpha2beta1 pathway. Int J Cancer 110: 788799.
  • Park HS, Park D, Bae YS (2006). Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1. Biochem Biophys Res Commun 339: 985990.
  • Pichard V, Berthois Y, Roccabianca M, Prevot C, Sarrazin M, Portugal H et al. (2006). Concomitant cell growth and differentiation are dependent on erbBl and integrin activation in an autonomously surviving colon adenocarcinoma: involvement of autocrine amphiregulin secretion. Anticancer Res 26: 27692783.
  • Rokutan K, Kawahara T, Kuwano Y, Tominaga K, Sekiyama A, Teshima-Kondo S (2006). NADPH oxidases in the gastrointestinal tract: a potential role of Nox1 in innate immune response and carcinogenesis. Antioxid Redox Signal 8: 15731582.
  • Sadok A, Bourgarel-Rey V, Gattacceca F, Penel C, Lehmann M, Kovacic H (2008). Nox1-dependent superoxide production controls colon adenocarcinoma cell migration. Biochim Biophys Acta 1783: 2333.
  • Salomon DS, Brandt R, Ciardiello F, Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183232.
  • Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S et al. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 18511857.
  • Sumimoto H (2008). Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. Febs J 275: 32493277.
  • Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K et al. (2001). ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222228.
  • Tominaga K, Kawahara T, Sano T, Toida K, Kuwano Y, Sasaki H et al. (2007). Evidence for cancer-associated expression of NADPH oxidase 1 (Nox1)-based oxidase system in the human stomach. Free Radic Biol Med 43: 16271638.
  • Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem et al. (2005). Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11: 74807489.
  • Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J (2004). Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64: 356362.
  • Vincenzi B, Santini D, Tonini G (2006). Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. Ann Oncol 17: 527528.
  • Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A, et al. (2007). Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther, 6, 114350.
  • Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998). Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275280.